53 results about "Protoporphyrin IX" patented technology

The invention relates to a culture medium for Haemophilus influenzae type b, characterized in that the source of protein nitrogen is of non-animal origin and comprises at least one plant peptone and in that the heme source consists of protoporphyrin IX. This medium serves in particular for the production of polyribosyl phosphate (PRP) and for the manufacture of a vaccine against Haemophilus influenzae type b meningitis.

The present invention discloses a use of N,N-dimethylethylenediamine or N,N-diethylethylenediamine or N-(2-aminoethyl)-trimethyl ammonium iodide or N-(2-aminoethyl)-triethyl ammonium iodide modified protoporphyrin. The N,N-dimethylethylenediamine or N,N-diethylethylenediamine or N-(2-aminoethyl)-trimethyl ammonium iodide or N-(2-aminoethyl)-triethyl ammonium iodide modified protoporphyrin has the following structure. Experiment results show that: the N,N-dimethylethylenediamine or N,N-diethylethylenediamine or N-(2-aminoethyl)-trimethyl ammonium iodide or N-(2-aminoethyl)-triethyl ammonium iodide modified protoporphyrin has a good in vitro photodynamic antibacterial performance, and provides good treatment effects for photodynamic treatments of mice infections caused by bacteria, fungi and the like.

Methods are described for detecting and quantifying occult blood in a biological sample using laser desorption mass spectrometry (LD MS). Biological samples that can be analyzed using various embodiments of the present invention include stool (fecal occult blood, FOB), and any bodily fluid including urine, cerebrospinal fluid and other bodily fluids. If the heme or heme metabolite is bound to protein, the sample is treated with acid before analysis to release the porphyrin. Some of the methods use LD MS with a time of flight analyzer (TOF) to detect and measure unbound heme, other hemoglobin metabolites and other molecules that have a porphyrin-based structure, e.g., bilirubin, biliverdin, protoporphyrin IX, and Zinc protoporphyrin in the biological sample. In other methods, matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) is used to detect and quantify the individual α- and β-polypeptide chains of hemoglobin.

A medical imaging system provides simultaneous rendering of visible light and fluorescent images. The system may employ dyes in a small-molecule form that remain in a subject's blood stream for several minutes, allowing real-time imaging of the subject's circulatory system superimposed upon a conventional, visible light image of the subject. The system may provide an excitation light source to excite the fluorescent substance and a visible light source for general illumination within the same optical guide used to capture images. The system may be configured for use in open surgical procedures by providing an operating area that is closed to ambient light.

The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate Bay 11-7085 BIO Brefeldin A (+)-Butaclamol Calcimycin Calmidazoliur chloride Chelerythrine chloride CK2 Inhibitor 2 CGP-74514A hydrochloride CGS-12066A meleate Dequalinium dichloride Dihydroouabain Diphenyleneiodonium chloride Emetine dihydrochloride hydrate GR 127935 hydrochloride Nifedipine 6-Nitroso-1,2-benzopyrone Palmitoyl-DL-Carnitine chloride Parthenolide PD 169316 1,10-Phenanthroline monohydrate 4-Phenyl-3-furoxancarbonitrile Prazosin hydrochloride Protoporphyrin IX disodium Quinacrine dihydrochloride Quabain Retinoic acid p-hydroxyanilide Rottlerin Sanguinarine chloride Tetraethylthium disulfide and SU 9516. The invention also provides new uses of these compounds, compounds such as for the preparation of the treatment of cancer, inhibit cancer cell, cancer stem cell growth and provides a new pharmaceutical composition for treating cancers

Provided is a therapeutic agent capable of treating allergic rhinitis in a safe, simple, and noninvasive manner substantially without side effects and physical distress to patients. Provided is a therapeutic agent for allergic rhinitis for 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-aminolevulinic acid or the derivative as an active ingredient, and used in ALA-PDT in which light having a wavelength of 400 nm to 700 nm is irradiated; and particularly provided is a therapeutic agent for allergic rhinitis in a locally applied solution form, a water-soluble ointment-dissolved form, a jelly-dissolved form, or the like. The therapeutic agent does not require the conduct of 5-aminolevulinic acid-based photodynamic diagnosis (ALA-PDD) for detecting a site of protoporphyrin IX (PpIX) accumulation radiating light having a wavelength of 610 nm to 650 nm under irradiation of excitation light having a wavelength of 380 nm to 420 nm before ALA-PDT.

The present disclosure relates to methods for detecting brain tumors and assessing the recurrence of such tumors by administering a pharmaceutical composition comprising 5-aminolevulinic acid (5-ALA) and detecting the conversion of 5-ALA to protoporphyrin IX (PPIX) associated with brain-derived microparticles.

This invention provides an abnormally-activated-cell apheresis-therapy apparatus for inhibiting the onset of or treating leukemia by removing abnormally activated cells, specifically abnormally activated leukocytes or leukemia progenitor cells, from blood. Said abnormally-activated-cell apheresis-therapy apparatus, which is an abnormally-activated-leukocyte apheresis-therapy apparatus that removes abnormally activated cells such as leukemia cells from blood, said cells having been made identifiable via high-concentration accumulation of protoporphyrin IX, is provided with the following: a blood-collection line, one end of which is provided with a needle for blood collection; a centrifugal separator that separates out a leukocyte fraction from blood sent down the blood-collection line; a cell sorter that removes abnormally activated cells from the separated-out leukocyte fraction; a light-exposure device that exposes the normal leukocyte fraction resulting from the removal of the aforementioned abnormally activated cells to light of a prescribed wavelength; and a return line that returns, to the patient, the normal leukocyte fraction and a return fluid comprising the blood components other than the leukocyte fraction.

This invention provides novel truncation mutants of a phytochrome from the bacterium Deinococcus radiodurans. When expressed either in bacteria or mammalian cells, these mutant phytochromes spontaneously incorporate biliverdin, a ubiquitous intermediate in heme catabolism, and become fluorescent in the infrared (IR) region. These phytochromes are the first genetically encoded labels that can be excited by far-red light and fluoresce in the true IR (>700 nm). If these mutants instead incorporate protoporphyrin IX, an intermediate in heme biosynthesis, illumination now generates significant amounts of singlet oxygen. Singlet oxygen is useful because it can be used to kill individual proteins or cells, detect long-range protein-protein interactions, or generate electron-microscopic contrast. The invention also relates to methods of making and using such proteins and protein variants.

It is to provide photodynamic therapy (PDT) and photodynamic diagnosis (PDD) which are suitable for the diagnosis and therapy of a part requiring a certain degree of deep penetration, such as subcutaneous cancer and lymph nodes surrounded by blood vessels and fat. This is solved by performing PDT and PDD targeting cancer by administering a composition comprising a photosensitizing agent such as a tetrapyrrole-based compound (photofrin, protoporphyrin IX, etc.) or ALAs such as 5-aminolevulinic acid (ALA), ALA methyl ester, ALA ethyl ester, ALA propyl ester, ALA butyl ester, ALA pentyl ester, or a hydrochloride, phosphate, or sulfate thereof followed by irradiation with excitation light at a wavelength of 480 to 580 nm.

The invention discloses a novel antifogging hybridization composite membrane for food packaging. The antifogging hybridization composite membrane comprises, by weight, 100-110 parts of base material,1.2-1.5 parts of modified antifogging agent, 2.0-2.5 parts of base-material graft and 0.3-0.5 part of nano inorganic filler, wherein the base material is the mixture formed by high-density polyethylene and methyl methacrylate-butadiene-styrene copolymer; the modified antifogging agent is obtained by subjecting polyethylene glycol-polyglutamic acid-polyalanine triblock copolymer to protoporphyrin IX Mn(III) chloride and sodium lauryl sulfonate modification; the base-material graft is graft copolymer obtained by grafting methacrylic acid to the main chain of the methyl methacrylate-butadiene-styrene copolymer under the effect of an initiator. The prepared novel antifogging hybridization composite membrane is excellent in antifogging effect and excellent in mechanical performance.

Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

The invention discloses a microneedle patch for enhancing accumulation of protoporphyrin IX in a solid tumor and a preparation method of the microneedle patch. The method comprises the following steps: dissolving albumin into a Duncheng culture medium, taking the albumin as a template, and adding CuCl2 and CaCl2 for mineralization to obtain CCP nanoparticles; cAT and 5-ALA are loaded to the surfaces of the CCP nano-particles through a one-step carbodiimide coupling method and an electrostatic adsorption method respectively, and CCPCA nano-particles are obtained; and loading the CCPCA nanoparticles and the microneedle matrix solution into a microneedle mold, and performing vacuum drying and demolding to obtain the microneedle patch for enhancing PpIX accumulation in the solid tumor. According to the microneedle patch, the PpIX and O2 level in a tumor can be increased through precise delivery of CAT and 5-ALA, meanwhile, guidance of real-time bimodal PpIX fluorescence imaging and photoacoustic blood oxygen imaging is provided, and the photodynamic treatment effect on different cancers is improved.

The present invention is a method for determining condition parameters for photodynamic therapy in which protoporphyrin IX accumulated within cells is irradiated with light after administration of 5-aminolevulinic acid to a subject. The method comprises the steps of calculating a regression curve representing a correlation between three condition parameters of the cell survival (Y), the amount (X) of protoporphyrin IX accumulated within cells, and the light irradiation energy density (P) in an experimental stage; and preliminarily selecting two condition parameters from among the cell survival (Y), the amount (X) of protoporphyrin IX accumulated within cells, and the light irradiation energy density (P) before the start of treatment, and determining the remaining condition parameter by using the regression curve. The photodynamic therapy can be optimized by such a technique.

In accordance with an aspect of the present invention, a 5-aminolevulinic-acid-based compound (ALA-based compound) is delivered locally to a tissue or organ within a subject's body. In another aspect, a method of diagnosis or treatment is provided which comprises: (a) locally delivering an ALA-based compound to a tissue or organ within a subject's body and (b) illuminating the tissue or organ with light having a wavelength suitable to induce fluorescence of protoporphyrin IX (PPIX). In some embodiments, a local therapeutic agent is delivered to the targeted tissue or organ for treatment. In another aspect, formulations containing the ALA-based compound are provided.